Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20221003002
TCTR20221003002
Unknown
Phase 4

Effect of SGLT2 inhibitor on Renal Function and Urinary [TIMP-2] x [IGFBP7] in Patients Hospitalized for Acute Heart Failure; A Randomized Controlled Trail

/A0 sites66 target enrollmentOctober 3, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAcute kidney injury and urinary [TIMP-2] x [IGFBP7] in patient hospitalized for acute heart failureAcute kidney injury, urinary [TIMP-2] x [IGFBP7], nephrocheck, acute heart failure, acute decompensated heart failure, SGLT2 inhibitor, renal function, biomarker

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Acute kidney injury and urinary [TIMP-2] x [IGFBP7] in patient hospitalized for acute heart failure
Sponsor
/A
Enrollment
66
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 3, 2022
End Date
April 30, 2023
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
/A

Eligibility Criteria

Inclusion Criteria

  • •1\. acute decompensated heart failure
  • •1\.1 dyspena at rest or dyspnea on minimal exertion
  • •1\.2 signs of pulmonary congestion
  • •1\.3 NT\- proBNP more than 1600 pg/ml or more than 2000 pg/ml in atrial fibrillation patients
  • •2\. No vasodilator intravenous within 6 hours
  • •3\. No vasopressor and inotropic drug intravenous within 6 hours

Exclusion Criteria

  • •1\. Type 1 diabetes
  • •2\. History of diabetic ketosis or ketosis
  • •3\. GFR (CKD\-EPI) \< 30 ml/min/1\.73 square meter
  • •4\. History of prior SGLT2 inhibitor
  • •5\. Systolic blood pressure \< 100 mmHg
  • •6\. Cardiogenic shock
  • •7\. History of percutaneous coronary intervention within 30 days before enrollment or planned for percutaneous coronary intervention
  • •8\. Immunosuppressive agent use
  • •9\. Acidemia with pH \< 7\.2
  • •10\. Sepsis or septic shock

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
The Renal Protective Effect Of SGLT2 Inhibitor Drug In Diabetics Patient Who Are Undergoing Per cutaneous Coronary Interventions.Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications
CTRI/2023/10/058896GSM Institute of Pharmaceutical Science
Active, not recruiting
Phase 1
The RECEDE-CHF TrialType 2 diabetes and heart failureMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2016-003968-39-GBniversity of Dundee/NHS Tayside23
Recruiting
Not Applicable
Investigation of renal protective effects of SGLT2 inhibitor by using renal doppler ultrasonography
JPRN-UMIN000028438Ogawa Red Cross Hospital60
Completed
Phase 4
Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome PreventionCongestive Heart Failure
NCT04778787I.M. Sechenov First Moscow State Medical University370
Completed
Phase 3
Evaluation Renoprotective Effect SGLT2 inhibitors on Prognosis of Transplant Kidney PatientsCondition 1: Diabetes mellitus type 2. Condition 2: Transplant Kidney.Type 2 diabetes mellitus with kidney complicationsKidney transplant statusE11.2Z94.0
IRCT20220708055414N1Orchidpharmed30